Bluejay Diagnostics, Inc. - BJDX Enterprise Value-to-Revenue Multiple

Official company branding of Bluejay Diagnostics Inc (BJDX)

Efficient reagent delivery to clinics supports the current trend, where the enterprise value to annual revenue multiple 0.00 indicates the value of this parameter for Bluejay Diagnostics (BJDX). Revenues are based on the sale of the Symphony platform and consumable cartridges. However, the anticipation of FDA approval for sepsis tests and a capital deficit create risks of new share issuances, which impacts the chart.

BJDX (Bluejay) EV/Sales Multiple history from 11/23/2025 to 11/19/2026

Financial and market metric breakdowns for Bluejay (BJDX)

- current quotes and average value forecast:
Fundamental company valuation:Bluejay Diagnostics, BJDX
Core merchandise of Bluejay Diagnostics Inc

For Bluejay Diagnostics (BJDX), which develops portable rapid blood analysis laboratories, the enterprise value assessment via EV/Sales reflects the market value of the business, accounting for net debt relative to annual revenue. The trend of this indicator allows investors to determine how effectively diagnostic innovations are being capitalized, while a sharp decline in the metric may signal a systemic decrease in the profitability of the operating model.

Competitor analysis for Bluejay Diagnostics

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|ProPhase - Business Value to Revenue|Enterprise Value-to-Revenue Ratio ainos.com|CODX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio HeartSciences (HSCS)|Company Value to Revenue Biomerica Inc. BMRA|EV/Sales Multiple CDIO (Cardio Diagnostics)|ONCO - Company Value to Revenue|VRAX: Company Value to Revenue|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue